A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

Trial Profile

A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Aug 2017 Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma is added to the trial,number of arms has changed from 2 to 3 ,hence number of patient has also changed from 42 to 92
    • 23 Aug 2017 Planned number of patients changed from 42 to 92.
    • 09 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top